Please assess the completion status of the following clinical trial:

Trial Title: The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Phase I:~  1. Male and female patients (≥18 years of age to 80)~ 2. Eligible for care at Brooke Army Medical Center~Phase II:~1. Met the criteria for qualification for a percutaneous liver biopsy and completed Phase I~2. Eligible for care at Brooke Army Medical Center~Exclusion Criteria:~* Phase I:~  1. Patients with excessive alcohol use will be excluded as defined as \>21 units of alcohol/week for men and 14 units of alcohol/week for women over a 2 year time frame. One drink unit or one standard drink is equivalent to a 12-ounce beer, a 4-ounce glass of wine, or a 1-ounce shot of hard liquor.~ 2. Patients with prior history of liver disease to include chronic hepatitis B or C, hemochromatosis, Wilson's disease, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, HIV, or prior documentation of NAFLD.~ 3. Patients on medications known to cause fatty liver disease: tamoxifen, corticosteroids, amiodarone, methotrexate, valproic acid~ 4. Patients carrying an implantable active medical device such as a pacemaker or a defibrillator~ 5. Pregnant women~Phase II:~1. CCTA/CAC only: GFR \<60 mls/min/1.73m2 or IV contrast dye allergy~2. CCTA/CAC only: contraindications to atrioventricular (AV) nodal blocking agents (high degree AV block without permanent pacemaker, asthma, allergy to nodal blocking agents).~3. Known CAD defined as previous PCI or CABG (Note: Subjects with CCTA within the past 12 months will not be excluded from study and repeat scan will not be needed but the results of that previous scan will be included in the prevalence and severity analysis.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Control (Type: None): The target population for this study is male and female patients (age 18 to 80) and will consist of retired and active military personnel and their dependents. There will be no race, ethnic, or gender limitations to enrollment.~The control group will be made of individuals who do not meet the qualifications for a liver biopsy.
- NAFLD (Type: None): The target population for this study is male and female patients (age 18 to 80) and will consist of retired and active military personnel and their dependents. There will be no race, ethnic, or gender limitations to enrollment.~The NAFLD group will be made of individuals who qualify for a liver biopsy and have histologically proven NAFLD.
- NASH (Type: None): The target population for this study is male and female patients (age 18 to 80) and will consist of retired and active military personnel and their dependents. There will be no race, ethnic, or gender limitations to enrollment.~The NASH group will be made of individuals who qualify for a liver biopsy and have histologically proven NASH.

Based on this trial design, predict the completion outcome and termination type (if applicable).